Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Segmented information

v3.24.1.1.u2
Segmented information
 12 Months Ended
Dec. 31, 2023
Segmented information  
Segmented information

18.Segmented information

The Company operates in one reportable operating segment, being the development and commercialization of therapies to treat progressive kidney disease. As the operations comprise a single reporting segment, amounts disclosed also represent segment amounts. All long-term assets of the Company are located in Canada.